Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Intervacc AB (publ) (IVACC.ST)
SEK1.25
-0.02 (-1.42%)
SE STO Healthcare Biotechnology
Address
Västertorpsvägen 135 129 44
Hägersten, SE
Hägersten, SE
CEO
Carl-Johan Dalsgaard
Website
intervacc.se
IPO
2017-04-07
ISIN SE0009607252
Description
Intervacc AB (publ) is a Swedish biotechnology company primarily engaged in the research and development of innovative vaccines designed to combat bacterial infections in animal health. The firm's vaccine pipeline targets various animals, including horses, piglets, and dairy cows, with its key product, Strangvac, specifically developed to prevent equine strangles. Beyond its current offerings, Intervacc is also advancing vaccines against Streptococcus suis and Staphylococcus aureus infections. In addition to vaccine development, the company distributes veterinary medicines and provides essential diagnostic services in veterinary bacteriology to clinics and stud farms. Headquartered in Hägersten, Sweden, Intervacc serves customers across the Nordic countries and the Baltic states.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
SEK1.25
-0.02 (-1.42%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
514.4K
Beta
0.16
Float Shares
328.95M
Free Float %
96.5%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.53% | -8.71% | -4.87% | +59.44% | +26.34% | +21.85% | -7.21% | -76.02% | -97.96% | -79.53% | -79.53% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
1.25
Ratings Trend (MoM)
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
8.79
Safe zone
Piotroski F-Score
1 / 9
Weak
MOAT Score
0 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+70.4% ★ Q1'26: -26.2% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+68.6% ★ Q1'26: +57.5% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-439.5% Q1'26: -357.6% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-422.5% Q1'26: -677.5% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-74.4% Q1'26: -84.7% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+236.9% Q1'26: +286.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.00× Q1'26: 0.00× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
48.00M
est: 48.00M (+0.0%)
|
35.60M
est: 38.41M (-7.3%)
|
12.14M
est: 14.56M (-16.6%)
|
4.78M
est: 5.00M (-4.4%)
|
5.24M
est: 21.10M (-75.2%)
|
9.68M
est: 18.00M (-46.2%)
|
8.02M
est: 9.78M (-18.0%)
|
11.79M
est: 13.00M (-9.3%)
|
20.09M
est: 25.00M (-19.7%)
|
16.00M
16.00M – 16.00M
-36.0% YoY
|
30.00M
30.00M – 30.00M
+87.5% YoY
|
164.00M
164.00M – 164.00M
+446.7% YoY
|
381.50M
381.50M – 381.50M
+132.6% YoY
|
| EBITDA |
-7.18M
est: -48.00M (+85.1%)
|
-16.15M
est: -38.41M (+57.9%)
|
-21.69M
est: -14.56M (-48.9%)
|
-19.39M
est: -5.00M (-287.9%)
|
-23.15M
est: -21.10M (-9.7%)
|
-57.73M
est: -18.00M (-220.7%)
|
-68.98M
est: -9.78M (-605.4%)
|
-58.75M
est: -13.00M (-351.9%)
|
-66.25M
est: -25.00M (-165.0%)
|
-16.00M
-16.00M – -16.00M
+36.0% YoY
|
-30.00M
-30.00M – -30.00M
-87.5% YoY
|
-164.00M
-164.00M – -164.00M
-446.7% YoY
|
-381.50M
-381.50M – -381.50M
-132.6% YoY
|
| EBIT |
-13.67M
est: -48.00M (+71.5%)
|
-30.92M
est: -38.41M (+19.5%)
|
-27.85M
est: -14.56M (-91.3%)
|
-25.57M
est: -5.00M (-411.4%)
|
-29.30M
est: -21.10M (-38.9%)
|
-64.03M
est: -18.00M (-255.7%)
|
-93.58M
est: -9.78M (-856.9%)
|
-77.28M
est: -13.00M (-494.4%)
|
-84.86M
est: -25.00M (-239.4%)
|
-16.00M
-16.00M – -16.00M
+36.0% YoY
|
-30.00M
-30.00M – -30.00M
-87.5% YoY
|
-164.00M
-164.00M – -164.00M
-446.7% YoY
|
-381.50M
-381.50M – -381.50M
-132.6% YoY
|
| Net Income |
-12.77M
est: -50.11M (+74.5%)
|
-27.49M
est: -32.04M (+14.2%)
|
-27.89M
est: -20.21M (-38.0%)
|
-25.60M
est: -25.65M (+0.2%)
|
-29.38M
est: -26.64M (-10.3%)
|
-64.16M
est: -71.70M (+10.5%)
|
-102.85M
est: -403.07M (+74.5%)
|
-75.52M
est: -255.12M (+70.4%)
|
-80.82M
est: -92.18M (+12.3%)
|
-65.42M
-65.42M – -65.42M
+29.0% YoY
|
-71.37M
-71.37M – -71.37M
-9.1% YoY
|
-38.66M
-38.66M – -38.66M
+45.8% YoY
|
—
— – —
+100.0% YoY
|
| SGA |
9.60M
est: 196.55M (-95.1%)
|
10.06M
est: 157.27M (-93.6%)
|
10.79M
est: 59.62M (-81.9%)
|
11.54M
est: 20.47M (-43.6%)
|
14.65M
est: 86.40M (-83.0%)
|
26.87M
est: 73.70M (-63.5%)
|
62.24M
est: 35.32M (+76.2%)
|
55.68M
est: 46.96M (+18.6%)
|
—
est: 90.30M (-100.0%)
|
57.79M
57.79M – 57.79M
-36.0% YoY
|
108.36M
108.36M – 108.36M
+87.5% YoY
|
592.36M
592.36M – 592.36M
+446.7% YoY
|
1.38B
1.38B – 1.38B
+132.6% YoY
|
| EPS |
-0.69
est: -0.57 (-21.6%)
|
-0.78
est: -0.36 (-114.9%)
|
-0.62
est: -0.23 (-170.9%)
|
-0.47
est: -0.29 (-61.7%)
|
-0.51
est: -0.30 (-69.0%)
|
-1.11
est: -0.81 (-36.7%)
|
-1.59
est: -1.36 (-17.3%)
|
-0.86
est: -0.86 (-0.2%)
|
-0.27
est: -0.31 (+12.9%)
|
-0.22
-0.22 – -0.22
+29.0% YoY
|
-0.24
-0.24 – -0.24
-9.1% YoY
|
-0.13
-0.13 – -0.13
+45.8% YoY
|
—
— – —
+100.0% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-11 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-08 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-07 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-06 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-05 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-04 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-66.28M
OE per share TTM
-0.29
Owner's Yield
-14.51%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
7.6%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
-56.6K
Shares Outstanding
340.81M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Carl-Johan Dalsgaard | Chief Executive Officer | 3M | — |
| Andrew Waller | Chief Scientific Officer | — | — |
| Anna-Carin Lagerlof | Sales & Marketing Director | — | female |
| Jan Persson | Chief Financial Officer | — | male |
| Patrik Hellberg | Chief Investment Officer | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for IVACC.ST
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
